Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 11, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-10

Reporting Person: ARCH Venture Partners IX, L.P. (10% Owner)
Reporting Person: ARCH Venture Fund IX Overage, L.P. (10% Owner)
Reporting Person: ARCH Venture Partners IX Overage, L.P. (10% Owner)
Reporting Person: ARCH Venture Partners IX, LLC (10% Owner)
Reporting Person: CRANDELL KEITH (10% Owner)
Reporting Person: BYBEE CLINTON (10% Owner)
Reporting Person: ARCH Venture Fund IX, L.P. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	444444	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Convertible Preferred Stock	$		Common Stock (11111110)		Indirect
Series A-1 Convertible Preferred Stock	$		Common Stock (13333332)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (555555)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (2222222)		Indirect

Footnotes

F1: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

F2: Each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into 1 share of Common Stock. The Preferred Stock has no expiration date.

F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.